Despite advances in surgery, chemo- and radiation-therapy, patients with glioblastoma multiforme (GBM) have a grim prognosis with less than 10% of patients surviving more than 5 years. Recent studies have shown potential of T and B-cell responses against GBM. However, existing technologies fail to elicit robust levels of anti-GBM immune responses with therapeutic efficacy. Therefore, there is a critical need for an alternative and effective strategy that can achieve strong T and B-cell responses against GBM. Our long-term research goal is to characterize the structure/function relationship governing immune activation with biomaterials. Our objective in this application is to understand how physicochemical properties of biomaterial-based vaccine platforms impact materials interactions with lymphoid tissues, with particular emphasis on (i) in vivo antigen (Ag) accumulation in lymph nodes, (ii) Ag presentation by antigen-presenting cells, and (iii) induction of cytotoxic CD8+ T lymphocyte (CTL) and antibody (Ab) responses against GBM. To that end, we have developed a novel lipid-based system, called interbilayer-crosslinked multilamellar vesicles (ICMVs). We show that ICMVs (1) efficiently transport Ag to local draining lymph nodes, (2) promote Ag presentation by antigen-presenting cells, (3) generate stronger CTL responses than other conventional adjuvants, including CpG in water-in-oil adjuvant, Montanide (arguably one of the strongest CTL adjuvant systems in clinical trials), and (4) exert potent therapeutic efficacy in murine tumor models, including intracranial GBM. Here, we will synthesize a series of new ICMVs with varying materials properties and determine the effects of biomaterials on immune activation and induction of CTL and Ab responses. We will evaluate their therapeutic efficacy in murine models of transplantable GBM as well as genetically induced GBM. We will also assess our strategy in combination with therapies designed to stimulate immune functions within GBM. Overall, these studies will improve our understanding of the biology-materials interfaces and may lead to new design principles for biomaterials engineered to elicit robust levels of immune responses, delay tumor growth, and prevent relapse. More broadly, the work proposed will address current technical limitations in vaccine technologies and potentially lead to a new treatment option for GBM patients.

Public Health Relevance

The proposed research is relevant to public health because these studies will improve our understanding of the biology-materials interfaces and may lead to new design principles for biomaterials engineered to elicit robust levels of immune responses, thereby addressing current technical limitations in vaccine technologies.

Agency
National Institute of Health (NIH)
Institute
National Institute of Biomedical Imaging and Bioengineering (NIBIB)
Type
Research Project (R01)
Project #
5R01EB022563-04
Application #
9727967
Study Section
Biomaterials and Biointerfaces Study Section (BMBI)
Program Officer
Rampulla, David
Project Start
2016-09-07
Project End
2020-05-31
Budget Start
2019-06-01
Budget End
2020-05-31
Support Year
4
Fiscal Year
2019
Total Cost
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Haase, Santiago; Garcia-Fabiani, María Belén; Carney, Stephen et al. (2018) Mutant ATRX: uncovering a new therapeutic target for glioma. Expert Opin Ther Targets 22:599-613
Kuai, Rui; Yuan, Wenmin; Son, Sejin et al. (2018) Elimination of established tumors with nanodisc-based combination chemoimmunotherapy. Sci Adv 4:eaao1736
Kamran, Neha; Li, Youping; Sierra, Maria et al. (2018) Melanoma induced immunosuppression is mediated by hematopoietic dysregulation. Oncoimmunology 7:e1408750
Park, Hyun-Ji; Kuai, Rui; Jeon, Eun Je et al. (2018) High-density lipoprotein-mimicking nanodiscs carrying peptide for enhanced therapeutic angiogenesis in diabetic hindlimb ischemia. Biomaterials 161:69-80
Kuai, Rui; Sun, Xiaoqi; Yuan, Wenmin et al. (2018) Subcutaneous Nanodisc Vaccination with Neoantigens for Combination Cancer Immunotherapy. Bioconjug Chem 29:771-775
Mendez, Flor M; Núñez, Felipe J; Zorrilla-Veloz, Rocío I et al. (2018) Native Chromatin Immunoprecipitation Using Murine Brain Tumor Neurospheres. J Vis Exp :
Ochyl, Lukasz J; Bazzill, Joseph D; Park, Charles et al. (2018) PEGylated tumor cell membrane vesicles as a new vaccine platform for cancer immunotherapy. Biomaterials 182:157-166
Nam, Jutaek; Son, Sejin; Ochyl, Lukasz J et al. (2018) Chemo-photothermal therapy combination elicits anti-tumor immunity against advanced metastatic cancer. Nat Commun 9:1074
Kuai, Rui; Sun, Xiaoqi; Yuan, Wenmin et al. (2018) Dual TLR agonist nanodiscs as a strong adjuvant system for vaccines and immunotherapy. J Control Release 282:131-139
Kamran, Neha; Alghamri, Mahmoud S; Nunez, Felipe J et al. (2018) Current state and future prospects of immunotherapy for glioma. Immunotherapy 10:317-339

Showing the most recent 10 out of 26 publications